Rifaximin
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
80621-81-4- Standard-SMILES
CO[C@H]1/C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C- Summenformel
- C43H51N3O11
- Durchschnittliche Molmasse
- 785,89 g/mol
Namen und Bezeichner
- Bevorzugter Name
- Rifaximin
- Englischer Name
- Rifaximin
- Summenformel
- C43H51N3O11
- Molmasse
- 785.89
Namen und Synonyme
RIFAMIXINXIFAXANEarthworm Extractl105normixl105svRiimimRIFACOLRifaxinRitacol
Datenbank-Bezeichner
- CAS
80621-81-4- PubChem CID
- 46783403
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 200 · 200-2050C (dec)
- Dichte
- 1.36 · 1.36±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- 1 mg/mL · ethanol: soluble1mg/mL
- Aggregatzustand
- powder
- pka
- 2.83 · 2.83±0.70(Predicted)
- Farbe
- dark orange
- Merck
- 14 · 14,8220
- Stabilität
- Hygroscopic
- Major Application
- forensics and toxicologypharmaceutical (small molecule)
- InChIKey
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N
- SMILES
- CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- 2
- hs_code
- 2941.90.3000
- RTECS-Nr.
- KD1576000
- Toxizität
- LD50 orally in rats: >2000 mg/kg (Borelli, Bertoli)
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Anwendungen
BeschreibungRifaximin is an antibiotic structurally related to rifamycin. It is reported to be efficacious in the treatment of gastrointestinal infections and hepatic encephalopathy, being highly active against Gram-positive and -negative aerobic and anaerobic bacteria. Due to poor systemic absorption, rifaximin is effective in presurgical sterilization of the GI tract.It displays good activity against a wide spectrum of bacteria, including Salmonella spp., S. aureus, and E. coli.
HistoryRifaximin was developed by Salix Pharmaceuticals, it is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of non-infectious gastrointestinal diseases like irritable bowel syndrome and hepatic encephalopathy. Rifaximin was originally approved by the US Food and Drug Administration (FDA) in May of 2004 for the management of traveler's diarrhea caused by noninvasive strains of Escherichia coli in patients aged >12 years. On March 24, 2010, rifaximin received an additional labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients aged ≥18 years with advanced liver disease.
VerwendenRifaximin is a non-absorbable semisynthetic Rifamycin antibiotic.
Anbieter100 Anbieter
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…